# Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer

> **NCT00788333** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 40 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** BMS-754807
- **DRUG:** trastuzumab (Herceptin®)

## Key facts

- **NCT ID:** NCT00788333
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2012-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00788333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00788333, "Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00788333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*